Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The ARCADIAN trial has received OCTRU Green Light approval and has now begun to open sites to recruitment!

ARCADIAN

FULL TITLE

A Phase I Trial of the Hypoxia Modifier Atovaquone in Combination with Radical Concurrent Chemoradiotherapy in Locally Advanced Non-Small Cell Lung Cancer

 

SHORT TITLE

ARCADIAN: Atovaquone with Radical ChemorADIotherapy in locally Advanced NSCLC

 

The ARCADIAN trial has received Green Light approval from OCTRU and subsequently opened to recruitment at its first site in Oxford.

Funded by CRUK, ARCADIAN aims to investigate whether the drug atovaquone can be safely given to patients undergoing chemoradiotherapy for Non-Small Cell Lung Cancer (NSCLC).

Atovaquone has previously been shown to reduce tumour hypoxia, a state which can cause resistance to traditional cancer treatments. If the study shows that it is safe to administer atovaquone with chemoradiotherapy, further studies would be planned to assess the efficacy of this combination treatment.

 

Find out more on the Department of Oncology website: https://www.oncology.ox.ac.uk/about-us/overview/clinical-trials/clinical-trial-portfolio/arcadian

Similar stories

WHiTE Four trial results!

OCTRU

The WHiTE Four trial has now published its results in The Bone & Joint journal.

FUTURE GB Trial opens to recruitment!

OCTRU

The FUTURE GB Trial has received OCTRU Green Light approval and is now open to recruitment!

HOPE-e study resumes recruitment of women with painful osteoarthritis in the hand

Main OCTRU

Researchers in Oxford are looking to recruit women who have painful osteoarthritis in joints of their hands, after resuming a study that was paused due to the COVID crisis.

HUSH trial opens to recruitment!

OCTRU

The HUSH trial has received OCTRU Green Light approval and is now open to recruitment!

Oxford researchers start new trial on the use of anti-TNF to treat Covid-19 in care homes

Main OCTRU Trials

Researchers at the University of Oxford are starting a new study to explore the effectiveness of the anti-tumour necrosis factor (anti-TNF) drug adalimumab as a treatment for patients with COVID-19 in the community, especially care homes. The AVID-CC trial, which will be conducted by Oxford Clinical Trials Research Unit (OCTRU), will enrol up to 750 patients from community care settings throughout the UK.

Operation Ouch!

OCTRU

CBBC's Operation Ouch have been helping to raise awareness of participation in clinical trials for children.